CF
RXRX icon

Corebridge Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Corebridge Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-123,182
Closed -$652K – 2255
2025
Q1 		$652K Sell
123,182
-523
-0.4% -$3.81K ﹤0.01% 1455
2024
Q4 		$836K Sell
123,705
-3,789
-3% -$25.5K ﹤0.01% 1407
2024
Q3 		$840K Buy
127,494
+16,284
+15% +$117K ﹤0.01% 1446
2024
Q2 		$834K Buy
+111,210
New +$970K ﹤0.01% 1430

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Corebridge Financial's RXRX Position: Q2 2025 in Review

Corebridge Financial sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 123,182 shares — an estimated $652K sold.

Corebridge Financial first reported a position in RXRX in Q2 2024 and held it in 4 quarters. The position peaked at $840K in Q3 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Corebridge Financial reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 123,182 Recursion Pharmaceuticals shares in Q2 2025, an estimated $652K.
  • Corebridge Financial first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Recursion Pharmaceuticals position peaked at $840K in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.